That's a wrap on #GAMRIC2025! See today's highlights over on LinkedIn - t.ly/nr1sV Thanks to all who attended and we look forward to seeing you again next year for #GAMRIC2026. @carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social

The final day of #GAMRIC2025 is off to a great start, with the day's session on understanding the differences between patient and product journeys in low income, middle income and high income countries. @carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social

The highlights of day 2 at #GAMRIC2025 are now live on our LinkedIn - t.ly/fgQ0i @carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social

Diagnostics are a critical part of tackling #AMR. But how can developers create products that achieve widespread global use? Experts are taking the stage now at #GAMRIC2025 to discuss the gaps and possible innovations. @carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social

Important discussions happening now on rare fungal pathogens, and antifungal R&D at #GAMRIC2025. @carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social

Tuberculosis and its #AMR drug discovery challenges have the focus for today's second session at #GAMRIC2025. Talks from Kelly Chibale, Steve Berthel, Dirk Schnappinger, Bree Aldridge, and Jansy Sarathy. @carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social

Day 2 of #GAMRIC2025 is starting with discussions of lower respiratory tract infections, and how innovators can address challenges in diagnosis, clinical trials and therapeutics. @carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social

A roundup of highlights from day one at #GAMRIC2025 is now live on our LinkedIn - www.linkedin.com/feed/update/... @carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social

A great way to round off day one at #GAMRIC2025 – listening to lightning talks from researchers who are showcasing their work in the poster session. @carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social escmid.bsky.social

What are the challenges and potential interventions of STIs and #AMR? Can policy move the needle on AMR before 2029? These are the questions being asked in the afternoon sessions of #GAMRIC2025. @carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social dp.bsky.social

In our second morning session of #GAMRIC2025, experts from around the world dive into the challenges and opportunities for how antimicrobial therapies can address the specific needs of newborns and children. @carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social

This morning, Charlotte Watts, David Peterson, Sam Barrell and Marc Gitzinger took the stage at #GAMRIC2025 to discuss on the global #AMR crisis, and how organisations and researchers can come together to develop solutions. @carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social

The inaugural Global AMR Innovators Conference (GAMRIC) has begun! Stay tuned for updates and join the conversation here or on Bluesky using #GAMRIC2025. @carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social

Help improve the diagnosis of chronic lung disease in primary care. We're creating a target product profile (TPP) for a Simple Lung Test with @asthmaandlung.org.uk & @nihrtechevalhrc.bsky.social If you work in diagnostics or lung health, take this survey to help refine our TPP:https://t.ly/vpHSv.

Angela has faced one of every parent's worst fears – twice. She lost her daughter to cancer, then her son was diagnosed at 5. Her story highlights the need for more and better targeted cancer therapies for children. Hear her full story: https://youtu.be/Yl2xNhvHiZA #ChildhoodCancerAwarenessMonth

When it comes to medical research, lived experience is a vital form of expertise. You can hear more from our COO, Karen Skinner, on why patient engagement is critical to effective drug development in a recent Keep It Science podcast episode. 🎧Listen now: https://t.ly/lTc_s

In April, we convened a summit to explore what needs to happen to bring CAR T-cell therapies to children with solid cancers. For #ChildhoodCancerAwarenessMonth, our Head of Childhood Cancer, David Jenkinson, reflects on the importance of embracing innovation and adopting new approaches: t.ly/yi7oX

Yesterday, our colleagues from across the UK gathered to reflect on the great work of the past few years, look ahead at exciting future plans, and have a great time together! It was inspiring to unite over our shared sense of purpose to make a difference in the lives of patients.

Rare disease is collectively common, affecting ~1 in 17 people in the UK. The LifeArc Translational Centres for Rare Disease each tackle a different area of unmet need, but together they're building a stronger rare disease research ecosystem. Learn more: https://t.ly/zAEj- #LifeArcTCRD

In 2024, we surveyed 130+ healthcare professionals to identify 12 childhood cancer indications with the greatest unmet needs. For each, we're hosting a Paediatric Bespoke Therapeutic Development Workshop to drive progress in these areas. #ChildhoodCancerAwarenessMonth

2026 industrial placements at LifeArc are now open for applications - https://www.lifearc.org/careers/early-careers/industrial-placements/ Get hands-on experience with scientists in our Stevenage labs. Placements are available in biological sciences, chemistry and bioinformatics.

This #ChildhoodCancerAwarenessMonth, our Head of Childhood Cancer joined the RARECast podcast to discuss unmet needs and share how C-Further is driving the development of bespoke therapies. 🎧Listen to the episode "Changing the Playbook on Childhood Cancers": t.ly/rFwv4

We are pleased to announce that Adrien Lemoine has been appointed to the permanent position of Chief Business Officer. He'll continue to lead our business development and commercial strategy, ensuring alignment between scientific innovation and business objectives.

We're proud to welcome @goshcharity.bsky.social as a C-Further partner. Their £10m commitment will help accelerate innovation toward our goal of building one of the world's fastest-growing child-first drug discovery pipelines: https://t.ly/9je1m @crhorizons.bsky.social @greatormondst.bsky.social

We have a fantastic opportunity for a Funding Manager! We're looking for the right person to lead and advise on funding activities, while building strong collaborations that drive vital life science R&D. Sound like you? Apply by 26 September: https://www.lifearc.org/career/funding-manager/

🎉Today marks one year of the LifeArc Translational Centres for Rare Disease. These four Centres are breaking down the barriers in rare disease research and accelerating the development of new tests and treatments. #RareDisease #LifeArcTCRD #OneYearOfImpact

We're developing a target product profile (TPP) for a simple lung test to diagnose chronic lung disease in primary care. If you work in diagnostics or lung health, we want to hear from you! 👉 Take this survey to help us refine our TPP: https://t.ly/vpHSv

Through collaboration comes progress. Our Paediatric Bespoke Therapeutic Development Workshops unite researchers, advocates and people with lived experiences to drive change in childhood cancer indications with the greatest unmet need. #ChildhoodCancerAwarenessMonth

We have an exciting opportunity for a Safety and Compliance Manager who will ensure LifeArc's scientific activities meet all H&S and regulatory requirements, while helping shape the facilities at our new London HQ. Apply by 22 September: https://t.ly/b6dqI

This July, as part of HDR UK Black Internship Programme, our data science team welcomed Varaidzo Mukwekwe for a 10-week internship. In this blog, Varaidzo shares her journey to joining the programme, and all she learned during her time with us - https://t.ly/UeBbf

Cardiff University research is exploring an antibody-based therapy for Alzheimer's, backed by us as part of our £30m commitment to @ukdri.ac.uk . Designed to enter the brain and block key drivers of inflammation, it could protect brain cells and help fill a major treatment gap.

It's #WorldCysticFibrosisDay. Over 11,000 people in the UK are affected by cystic fibrosis, and there is still no known cure. With the @cysticfibrosis.org.uk, we've jointly invested in a network of hubs to help address areas of unmet medical need and improve how lung health is managed in the UK.

We're working with Professor James Chalmers at the University of Dundee to analyse NHS & EMBARC data – spotting early signs that could fast-track patients to the right care.

As part of our partnership with @ukdri.ac.uk, we're funding @edinburgh-uni.bsky.social research into combination therapies for MND. By repurposing well-tolerated drugs targeting key drivers of disease, the team aims to fast-track promising combinations into MND-SMART – the UK's largest MND trial

It's #ChildhoodCancerAwarenessMonth, and we're calling for a shift in how children with cancer are treated. Children deserve bespoke therapies, designed for the unique biology of their cancers, that not only target the disease but also prioritise quality of life and long-term health.

In one month, #GAMRIC2025 will be happening in London! We can't wait to gather with the global AMR community. We'll be posting live from the sold-out event (1 to 3 October) with the latest in AMR research and progress. www.gamric.org @gardp.bsky.social @carb-x.bsky.social @escmid.bsky.social

Better treatments. Better decisions. Better trials. That's what we set out to achieve when we launched the Childhood Cancer Translational Challenge last September. One year on, here's how we've been delivering on that promise. #ChildhoodCancerAwarenessMonth

Hear from our Chief Operating Officer, Karen Skinner, on the Keep It Science podcast as she shares what it takes to make real change for people living with rare diseases. ‪Thank you @kuglerelisabeth.bsky.social‬, for such a great discussion. 🎧Listen now: https://youtu.be/L2GvDNGV9BE?feature=shared

Childhood cancers need bespoke and innovative treatments. Our team of targeted protein degradation scientists, alongside 9 of the world's leading cancer research centres, are part of PROTECT, funded by @cancergrand.bsky.social to develop new drug approaches for hard-to-treat childhood cancers.

Since 2022, we've been growing our induced pluripotent stem cell (iPSC) capability to support research in motor neuron disease. Last year, we generated over 1 billion high-quality iPSC-motor neurons, representing both disease and healthy cells, to advance drug discovery projects.

With dementia diagnoses rising, so is the need for scalable, data-driven solutions in the health system. By supporting MinderCare, we aim to help shape better care for thousands more people in the future. https://www.the-independent.com/news/health/dementia-diagnosis-nhs-symptoms-b2814004.html

In 2024, we held 4 workshops with our MND Insights Group, conducted 2 community surveys and published the MND Insights Report, sharing the findings with researchers and decision-makers. You can find out more about this group and the report here: www.lifearc.org/project/mnd-...

🧩 Are you involved in rare disease research in the UK? RDR UK & @lifearc.bsky.social are building a tool to map the rare disease research landscape — and your input matters! Researchers, patients, families, carers & rare disease advocates — 📝please take the survey tinyurl.com/RDRLDproject

At 61, Gaynor Hardman was diagnosed with bronchiectasis, an overlooked and misunderstood chronic respiratory disease. It wasn't until Gaynor was hospitalised that she received the right care and information to manage her condition. Read Gaynor's story: t.ly/YQbuZ

From clinical trials to real-world use, we can help you navigate the clinical development journey. Whether it's a therapy, diagnostic, device, or other medical technology, our experienced team is here to support you every step of the way. 🔗 Learn more here: bit.ly/3V0hcqW

We're backing the HERON study, led by Oxford NIHR HRC, to identify barriers to diagnosing chronic lung conditions in primary and community care. Findings will guide the use of HealthTech to improve diagnosis. Lea... http://bit.ly/410YtPD?utm_campaign=coschedule&utm_source=bluesky&utm_medium=LifeArc

Our partners can benefit from: ✅ Funding and investment ✅ Personalised strategic advice ✅ Industrial know-how to develop industry-ready solutions Collaborate with us: https://www.lifearc.org/work-with-us/?utm_campaign=coschedule&utm_source=bluesky&utm_medium=LifeArc.

We're proud to have supported research from @sheffielduni.bsky.social which is now being taken forward into clinical trials. The team designed a novel gene therapy to address the root cause of spastic paraplegia 47 – a rare progressive neurological disorder causing gradual loss of motor function.

If you're working on a therapeutic or target validation project for childhood cancer and want to progress your work, submit an expression of interest to C-Further, a global consortium we launched with @crhorizons.bsky.social. 🗓️ Deadline: 1 September 🔗 Apply now: t.ly/FPAAG

We're funding the HERON study, led by Oxford NIHR HRC, to gather insights on unmet needs in managing chronic respiratory conditions in primary and community care. Take part in this survey and help us improve care: http://bit.ly/40W0ZGO?utm_campaign=coschedule&utm_source=bluesky&utm_medium=LifeArc